Daniel provides practical and strategic solutions as transactional and general counsel to clients as they navigate legal and regulatory issues and opportunities. He focuses on mergers and acquisitions, public and private securities offerings, restructurings, corporate governance, and a wide-range of commercial transactions. He also regularly advises public companies on all matters related to continuous and periodic disclosure.
NexGen Energy Ltd. completed a bought deal financing consisting of 33,400,000 common shares at a price of $4.50 per common share for gross proceeds of approximately $150 million
On October 1, 2018, MediPharm Labs Corp. (formerly POCML 4 Inc.) (TSXV: LABS) (“MediPharm Labs” or the “Company”) completed its business combination with MediPharm Labs Inc. (the “Target”), which resulted in a reverse take-over (“RTO”) of the Company by the shareholders of the Target and constituted the “Qualifying Transaction” of the Company as such term is defined in the policies of the TSX Venture Exchange (the “TSXV”).
Mettrum Health Corp. (Mettrum) completed the sale of all of its issued and outstanding shares to Canopy Growth Corporation (Canopy) by plan of arrangement, whereby Mettrum shareholders received 0.7132 common shares of Canopy for each Mettrum common share held, representing consideration of $8.42 per common share and a total transaction value of approximately $430 million, based on the respective closing prices prior to announcement of the transaction.
